Milae Bioresources KRX:218150KOSDAQ
미래생명자원 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, Milae Bioresources reported revenue of ₩19.3bn, up 15.4% year on year, and operating profit of ₩698m. Milae Bioresources (미래생명자원) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Milae Bioresources quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩19.3bn | +15.4% | ₩698m margin 3.6% | ₩27m |
| Q1 2026 | ₩17.0bn | +15.9% | ₩439m margin 2.6% | ₩537m |
| Q4 2025 derived | ₩17.4bn | +25.2% | −₩3.3bn margin −19.2% | −₩5.0bn |
| Q3 2025 | ₩18.7bn | +0.9% | ₩1.2bn margin 6.6% | ₩946m |
| Q2 2025 | ₩16.8bn | +7.6% | ₩503m margin 3.0% | ₩167m |
| Q1 2025 | ₩14.7bn | +1.8% | ₩155m margin 1.1% | ₩570m |
| Q4 2024 derived | ₩13.9bn | -6.7% | −₩253m margin −1.8% | −₩996m |
| Q3 2024 | ₩18.5bn | +14.0% | ₩551m margin 3.0% | ₩603m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Milae Bioresources top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Milae Bioresources news Korean headlines
No articles yet.